Mortality risk did not differ significantly after AFF vs after hip or ST/FS fractures among men receiving bisphosphonates for fracture prevention.

No increase in subtrochanteric or diaphyseal femur fractures was seen with denosumab use compared with bisphosphonates in 4 ...

Bisphosphanates are used primarily for the prevention and treatment of osteoporosis, and are also indicated for osseous complications of malignancy. In addition to their bone resorption properties, ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Bone tissue constitutes a fertile ‘soil’ for metastatic tumours, notably breast cancer. High concentrations of growth factors in bone matrix favour cancer cell proliferation and survival, and a ...

Bisphosphonates are medications that used to treat bone loss and are the most common agent to be prescribed for osteoporosis. These drugs can also reduce fracture risk in cases of previous fracture.

Labeling change adds warning about possible risks of long-term use of osteoporosis drugs The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk ...

The bone metastasis in solid tumors market is expanding due to rising incidences of metastasizing solid tumors like breast, prostate, lung cancer, and renal cell carcinoma. This growth is fueled by ...

BROOKLYN, NY — Authors of a new analysis say the US Food and Drug Administration (FDA) should consider revisiting its investigation of the atrial-fibrillation (AF) risk with certain osteoporosis drugs ...

The American College of Physicians updated its 2017 guideline on pharmacologic treatment of osteoporosis or low bone mass to prevent fractures in adults. In a shift from previous recommendations, the ...